These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 14555515)

  • 1. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
    Jensen BV; Johansen JS; Price PA
    Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
    Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
    Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
    Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C
    Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
    Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
    Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
    Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.
    Kim SH; Das K; Noreen S; Coffman F; Hameed M
    World J Surg Oncol; 2007 Feb; 5():17. PubMed ID: 17286869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum YKL-40, a new prognostic biomarker in cancer patients?
    Johansen JS; Jensen BV; Roslind A; Nielsen D; Price PA
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):194-202. PubMed ID: 16492905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.
    Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
    Cancer; 2002 Jul; 95(2):267-74. PubMed ID: 12124825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
    Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
    Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer.
    Johansen JS; Cintin C; Jørgensen M; Kamby C; Price PA
    Eur J Cancer; 1995; 31A(9):1437-42. PubMed ID: 7577068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
    Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
    Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
    Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum YKL-40 level in patients with small cell lung cancer is related to early death.
    Johansen JS; Drivsholm L; Price PA; Christensen IJ
    Lung Cancer; 2004 Dec; 46(3):333-40. PubMed ID: 15541818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer.
    Roslind A; Knoop AS; Jensen MB; Johansen JS; Nielsen DL; Price PA; Balslev E
    Breast Cancer Res Treat; 2008 Nov; 112(2):275-85. PubMed ID: 18157633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival.
    Johansen JS; Brasso K; Iversen P; Teisner B; Garnero P; Price PA; Christensen IJ
    Clin Cancer Res; 2007 Jun; 13(11):3244-9. PubMed ID: 17545529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum YKL-40 and colorectal cancer.
    Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
    Br J Cancer; 1999 Mar; 79(9-10):1494-9. PubMed ID: 10188896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
    Dehn H; Høgdall EV; Johansen JS; Jørgensen M; Price PA; Engelholm SA; Høgdall CK
    Acta Obstet Gynecol Scand; 2003 Mar; 82(3):287-93. PubMed ID: 12694127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.
    Høgdall EV; Johansen JS; Kjaer SK; Price PA; Christensen L; Blaakaer J; Bock JE; Glud E; Høgdall CK
    Oncol Rep; 2003; 10(5):1535-8. PubMed ID: 12883737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery.
    Zhu CB; Chen LL; Tian JJ; Su L; Wang C; Gai ZT; Du WJ; Ma GL
    Ann Surg Oncol; 2012 Mar; 19(3):817-25. PubMed ID: 21861215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?
    Coskun U; Yamac D; Gulbahar O; Sancak B; Karaman N; Ozkan S
    Neoplasma; 2007; 54(4):348-52. PubMed ID: 17845129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.